A second dose of the measles vaccine-MVC2 will be introduced by
government next year as a strategy aimed at eliminating measles in the
According to officials from the Uganda National Expanded Programme (UNEPI) with
the introduction of another dose, medics will administer the first vaccine-MVC1
at nine months and the second at 18 months.
Dr Alfred Driwale, the programme manager UNEPI says the
introduction of a second dose is critical because it will protect children who
are younger than nine months and are susceptible to the disease.
//Cue in; “The measles virus…
Cue out…are younger.”//
Driwale adds that while the uptake of the measles vaccine has improved in the
country and stands at over 90 percent, a second dose is needed to boost up the
“We will not eliminate measles unless we introduce a second dose. We have tried
to eliminate the disease using one dose, and it has become obvious that we
cannot do it, especially in younger children,” he explained.
Measles is still one of the leading vaccine-preventable killer diseases in
the country. According to a recent WHO report, ‘Progress towards Regional
Elimination of Measles-Worldwide’, Uganda recorded 150 measles-related deaths
in 2019. In 2018, the number stood at 80.
The 2009 WHO Measles Vaccination Paper, encouraged countries to introduce MCV2
only if they had achieved 80 percent vaccine coverage for MCV1 concurrently for
at least three years.
The government introduced the Measles-Rubella Vaccine in 2019. At the moment,
health ministry officials say that both the vaccines offer protection against
the disease. They are however still deciding whether both vaccines can be given
interchangeably with children receiving one of each at scheduled timelines.
Scientists recommend that two MR vaccines be given at between 12-15 months of
age and the second dose at 4 through to 6 years of age. Unlike the MR vaccines
which protect against Rubella or German measles, the MVC 1or 2 vaccines can
only protect against measles.
A source from the health ministry says they
are still trying to evaluate all logistical aspects like cost of one vaccine
over the other before a decision is made on what should be used or whether both
vaccines can be used at different times.